By Rebecca Thurlow

SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) said Wednesday it has launched its foam dermatology products Fabior and Sorilux in the U.S., after acquiring the marketing rights from GlaxoSmithKline (GSK) in August.

Fabior is a topical treatment for acne, the most prevalent skin disease in the U.S., affecting as many as 50 million people.

The market for topical acne treatments is significantly larger than the oral antibiotic acne market Mayne already participates in via the sale of its Doryx branded products. Topical products are used more frequently by acne patients across the disease spectrum ranging from mild to severe cases, Mayne said.

Sorilux is a foam that treats plaque psoriasis of the scalp and body, which affects up to six million Americans each year.

- Write to Rebecca Thurlow at rebecca.thurlow@wsj.com

(END) Dow Jones Newswires

January 10, 2017 17:13 ET (22:13 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Mayne Pharma (ASX:MYX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Mayne Pharma Charts.
Mayne Pharma (ASX:MYX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Mayne Pharma Charts.